Caidya announced it combined with Simbec-Orion to form a specialty clinical CRO platform spanning Europe, the Americas, APAC and China, with operations anchored by early-phase clinical pharmacology. Simbec-Orion brings a 48-bed Phase I clinical pharmacology unit in Europe and deep experience supporting oncology and rare disease development from first-in-human through registration. The merged organization will operate under CEO Barbara Lopez Kunz, with Fabrice Chartier leading Simbec-Orion operations within the combined company. The deal targets sponsors seeking an integrated development partner that can reduce handoffs across early clinical studies and registration-stage execution for complex programs.